Blueprint Comments

RFI Comments

The Trump Administration's request for information regarding the reduction of out-of-pocket prices for medication has been the most important topic at the intersection of policy and healthcare of 2018. Creating a blueprint of action to address what policies could be enacted to reduce out-of-pocket costs for patients, the Administration carefully scrutinized PBMs, drug manufacturers, and a variety of anti-transparency measures such as gag clauses. Their request garnered well over 2,000 responses at the Department of Health and Human Services from a variety of concerned stakeholders on all sides of the issue. Secretary Alexander Azar has appeared in the press and before Congress to bring the issue of sky-rocketing costs for patients to light in the public sphere. 

‚Äč

Attached below are the comments co-authored by the Coalition to Protect Patient Choice with Consumers Union, Consumer Action,  and US PIRG.

 

Additionally, there are comments and letters submitted by: Patients for Affordable Drugs (P4AD), I-MAK, Alliance for Transparent and Affordable Prescriptions (ATAP), KEI, PhRMA, National Business Group on Health (NBGH), Coalition of State Rheumatology Organizations (CSRO), and Families USA and Public Citizens.

For too long, there’s been a lot of talk on drug prices, and no action. Drug companies have insisted we can have new cures or affordable prices, but not both.

 

I’m not interested in hearing those talking points anymore, and neither is the President.

-Alex Azar